
US formulary review | A clearer argument deserves a clearer challenge
A formulary discussion needs more than a persuasive summary of a medicine. The committee has to see which evidence applies, what remains uncertain and what adoption would require in its own setting. We want a review process to make a strong argument easier to challenge, so clinical and operational decision-makers can distinguish an attractive proposition from one that survives scrutiny.
In development · Intended scope and questions for evaluation
The organisation.
The people around it.
The United States, India, Australia and Singapore reading routes explore questions for local evaluation. They do not establish overseas deployment, contracts or transferable clearance.
The people involved
Health systems, pharmacy organisations, payers and research partners in separately assessed jurisdictions.
The dependencies
Local providers, pharmacies, payers, professional reviewers, regulators, commissioners and source-rights owners as applicable.
What to examine
Local intended use, evidence applicability, data permissions, contracting, funding and the evaluation and assurance route.
An illustrative set of programme relationships. The actual participants, authority, funding and permissions must be established for the defined setting. Explore every organisation perspective.
A committee has a particular remit
A hospital committee, health-plan team and Medicare plan sponsor do not make identical decisions. The first brief would state the committee’s remit, population and decision authority. The buyer may be the pharmacy leader responsible for preparing material rather than the committee itself. The incentive is a more complete and efficient review, not a predetermined listing outcome or an automated recommendation to substitute one treatment for another.
Use the right policy frame
CMS formulary guidance provides Medicare-specific context (CMS, n.d.). It would not be applied indiscriminately to a hospital’s internal formulary or a commercial contract. We would identify which official documents are relevant and preserve their dates. Any local rule, exception process or implementation condition would need confirmation from the sponsor. The output should separate public policy context from the organisation’s own authorised procedure so readers can see what governs the decision.
A first pilot built around one question
We propose a controlled evidence-preparation exercise for a single committee question. Inputs could include an agreed question, a bounded set of publications, public policy documents and local implementation criteria. The comparator would be the current review method. Both methods would have the same source window and deadline. A qualified reviewer would check citations, population relevance, uncertainty and the completeness of implementation considerations.
Separate clinical evidence from affordability
A clinical result, a published price and a budget-impact assumption answer different questions. We would keep them in separate parts of the brief, with explicit source and perspective. The organisation would need to supply authorised local assumptions for a meaningful financial scenario. A public acquisition benchmark cannot establish the buyer’s net price. Any clinical comparison would remain subject to appropriate professional appraisal, including its applicability to the stated population.
Make the missing information productive
The output should explain what would change the committee’s confidence: a more relevant comparator, longer follow-up, a local resource estimate or clarification of an operational condition. We would retain negative findings and evidence that weakens the proposed case. Missing evidence would not be filled with plausible prose. A concise uncertainty register can be more valuable than a longer summary if it makes the next review task clear.
Evaluate the preparation, not the vote
Proposed measures include material omission rate, citation accuracy, reviewer effort and whether local implementation questions are visible. The committee’s eventual vote would not be a simple success metric for the software. A rejection can be the right decision, and a positive decision can still rely on evidence outside the pilot. We would report additional checking required so the apparent efficiency is not achieved by moving hidden work to senior reviewers.
What a commercial next step needs
We would stop if sources cannot be verified, the question exceeds available expertise or the method repeatedly conceals important uncertainty. Continuation would require a repeatable preparation need and evidence that reviewers find the output useful without losing control. A paid evaluation could then specify a bounded portfolio of questions. It would not promise formulary acceptance, payer endorsement or clinical validation of PHARMORIS itself.
Sources and reading context
Official source context checked on 13 October 2026. The study design above is a NEUVIOR proposal for discussion, not a reported deployment or result.
CMS (n.d.) Formulary Guidance. Available at: https://www.cms.gov/medicare/coverage/prescription-drug-coverage/formulary-guidance (Accessed: 14 October 2026).
Discuss a committee evidence study
Bring the decision you need to make, the person accountable for it and the evidence you can use. We can then discuss whether a bounded PHARMORIS evaluation is the right next step.
Bring the question
your organisation
needs to move.
Tell us where the programme gets stuck, who is affected and what a worthwhile evaluation would help you decide.
Discuss a PHARMORIS evaluationAn initial conversation should describe the organisational question. Agree the purpose and information requirements before sharing records.